| Summary: | Breakthrough pain is described as a transitory exacerbation of pain that occurs despite a background of adequately controlled pain. More than half of patients with cancer pain likely experience breakthrough pain. On average, patients may experience between four to six episodes of breakthrough pain daily, and the mean duration of each episode is approximately 30 minutes. Breakthrough pain has a rapid onset that can reach peak intensity in as little as one minute. Patients have consistently reported that breakthrough cancer pain negatively affects their daily living activities and quality of life. Managing patients with breakthrough cancer pain commonly involves prescribing them short-acting opioids as rescue medications, including immediate-release (IR) morphine, oxycodone, and hydromorphone. Fentora is a fentanyl buccal/sublingual effervescent tablet, the principal therapeutic action for which is analgesia. The objective of this review was to perform a systematic review of the beneficial and harmful effects of Fentora for the management of breakthrough pain in cancer patients aged 18 years and older who are already receiving and who are tolerant to continuous opioid therapy for their persistent baseline cancer pain
|
|---|